BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 24194567)

  • 1. Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer.
    Lee BY; Hochgräfe F; Lin HM; Castillo L; Wu J; Raftery MJ; Martin Shreeve S; Horvath LG; Daly RJ
    Mol Cancer Ther; 2014 Jan; 13(1):190-201. PubMed ID: 24194567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
    Lin HM; Lee BY; Castillo L; Spielman C; Grogan J; Yeung NK; Kench JG; Stricker PD; Haynes AM; Centenera MM; Butler LM; Shreeve SM; Horvath LG; Daly RJ
    Prostate; 2018 Mar; 78(4):308-317. PubMed ID: 29314097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1).
    Hour TC; Chung SD; Kang WY; Lin YC; Chuang SJ; Huang AM; Wu WJ; Huang SP; Huang CY; Pu YS
    Arch Toxicol; 2015 Apr; 89(4):591-605. PubMed ID: 24888374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
    Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G
    Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.
    Wu F; Lin Y; Cui P; Li H; Zhang L; Sun Z; Huang S; Li S; Huang S; Zhao Q; Liu Q
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):999-1006. PubMed ID: 29605876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway.
    Luo S; Shao L; Chen Z; Hu D; Jiang L; Tang W
    Exp Cell Res; 2020 May; 390(2):111981. PubMed ID: 32234375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.
    Yu L; Wu X; Chen M; Huang H; He Y; Wang H; Li D; Du Z; Zhang K; Goodin S; Zheng X
    Int J Med Sci; 2017; 14(4):356-366. PubMed ID: 28553168
    [No Abstract]   [Full Text] [Related]  

  • 8. MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
    Armstrong CM; Liu C; Lou W; Lombard AP; Evans CP; Gao AC
    Prostate; 2017 Jun; 77(9):1020-1028. PubMed ID: 28485104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer.
    Lin HM; Nikolic I; Yang J; Castillo L; Deng N; Chan CL; Yeung NK; Dodson E; Elsworth B; Spielman C; Lee BY; Boyer Z; Simpson KJ; Daly RJ; Horvath LG; Swarbrick A
    Sci Rep; 2018 May; 8(1):7820. PubMed ID: 29777112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK/mTOR-mediated autophagy.
    Lin JZ; Wang WW; Hu TT; Zhu GY; Li LN; Zhang CY; Xu Z; Yu HB; Wu HF; Zhu JG
    Cancer Lett; 2020 Jan; 469():481-489. PubMed ID: 31738958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells.
    Slack JK; Adams RB; Rovin JD; Bissonette EA; Stoker CE; Parsons JT
    Oncogene; 2001 Mar; 20(10):1152-63. PubMed ID: 11313859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells.
    Liu L; Lou N; Li X; Xu G; Ruan H; Xiao W; Qiu B; Bao L; Yuan C; Huang X; Wang K; Cao Q; Chen K; Yang H; Zhang X
    Oncol Rep; 2017 Jun; 37(6):3651-3659. PubMed ID: 28498452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of cabazitaxel-resistant mechanism in human castration-resistant prostate cancer.
    Hongo H; Kosaka T; Oya M
    Cancer Sci; 2018 Sep; 109(9):2937-2945. PubMed ID: 29989268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells.
    Wang Q; He WY; Zeng YZ; Hossain A; Gou X
    Int Urol Nephrol; 2018 Apr; 50(4):675-686. PubMed ID: 29460131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro.
    Du Z; Li L; Sun W; Wang X; Zhang Y; Chen Z; Yuan M; Quan Z; Liu N; Hao Y; Li T; Wang J; Luo C; Wu X
    Int J Oncol; 2018 Jul; 53(1):99-112. PubMed ID: 29658567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of testicular nuclear receptor 4 in chemo-resistance of docetaxel in castration-resistant prostate cancer.
    Chen B; Yu S; Ding X; Jing C; Xia L; Wang M; Matro E; Rehman F; Niu Y; Li G; Chang C
    Cancer Gene Ther; 2014 Oct; 21(10):411-5. PubMed ID: 25104727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells.
    Halder J; Landen CN; Lutgendorf SK; Li Y; Jennings NB; Fan D; Nelkin GM; Schmandt R; Schaller MD; Sood AK
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8829-36. PubMed ID: 16361572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific amino acid dependency regulates invasiveness and viability of androgen-independent prostate cancer cells.
    Fu YM; Yu ZX; Li YQ; Ge X; Sanchez PJ; Fu X; Meadows GG
    Nutr Cancer; 2003; 45(1):60-73. PubMed ID: 12791506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
    PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.